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Aortobifemoral graft infection with Mycobacterium
tuberculosis: Treatment with abscess drainage,
debridement, and long-term administration of
antibiotic agents
Joseph D. Raffetto, MD,a,c John Bernardo, MD,b and James O. Menzoı´an, MD,a Boston, Mass
Aortic graft infection with Mycobacterium tuberculosis is rare. We report a patient with a Dacron aortobifemoral prosthetic
graft infection secondary to tuberculosis. The infection was successfully treated with surgical drainage without removal
of the graft, and long-term antimycobacterial medications. A review of the literature contains only 1 other report of
tuberculosis graft infection and treatment. We discuss a rare form of aortic graft infection from M tuberculosis and its
treatment. (J Vasc Surg 2004;40:826-9.)CASE REPORT
The patient was a 56-year-old Indian woman who had under-
gone aortobifemoral (ABF) bypass because of aortoiliac occlusive
disease with Dacron in 1999 to treat Takayasu arteritis. In addition
the patient had undergone left-sided carotid endarterectomy, and
had an occluded left subclavian-axillary artery and stenosis of the
right subclavian artery from arteritis. The diagnosis of Takayasu
arteritis was clinical, based on the pattern of arterial involvement,
imaging studies, elevated erythrocyte sedimentation rate (ESR),
and use of steroids continuously since 1999. In 2000 the patient
was taking 60 to 80 mg/d of prednisone to treat active arteritis,
and results of a purified protein derivative (PPD) test were positive.
The patient received isoniazid prophylaxis for 6 months. Long-
term prednisone therapy was continued, to control arteritis; and
methotrexate was initiated, without success. In August 2002, in an
attempt to decrease the steroid dose and control the Takayasu
arteritis (ESR, 118), 2 doses of infliximab (Remicade; anti–tumor
necrosis factor- monoclonal antibody) was tried. However, fever
(temperature, 40°C) developed, and the infliximab was discontin-
ued. In September 2002 the patient continued to have fever, and
blood cultures, lumbar puncture, and imaging studies were per-
formed. An abdominal computed tomography (CT) scan demon-
strated left-sided para-aortic and retroperitoneal lymphadenopa-
thy, and a biopsy specimens were obtained percutaneously. At 3
weeks cultures from the cerebrospinal fluid and lymph node spec-
imens grew Mycobacterium tuberculosis, which required multiple
antimycobacterial drugs. It was thought that reactivation of tuber-
culosis had occurred secondary to aggressive immunosuppressive
therapy. The CT scan demonstrated that the lymphadenopathy
had resolved, repeat cerebrospinal fluid cultures were normal, and
From the Departments of Surgery,a and Medicine,b Boston University
Medical Center, and the West Roxbury Veterans Affairs Boston Health-
care System.c
Competition of interest: none.
Reprint requests: Joseph D. Raffetto, MD, VA Boston Healthcare System,
Department of Surgery, 112, Section Of Vascular Surgery, 1400 VFW
Parkway, West Roxbury, MA 02132 (e-mail: joseph.raffetto@med.va.gov).
0741-5214/$30.00
Copyright © 2004 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2004.07.041826the patient remained afebrile until March 2003. In May 2003 she
had a 2-month history of malaise, anorexia, weight loss, and fever
(temperature, 39°C); the white blood cell count (WBC) was
elevated, to 16,000/mm3, and the patient had left lower quadrant
abdominal pain and left groin pain. Examination revealed well-
healed abdominal and groin incisions free of erythema, sinus tracts,
or masses, with tenderness of the left flank and groin. The lower
extremities had normal pulses. A repeat abdominal CT scan dem-
onstrated a complex abscess involving the left limb of the ABF graft
and the left psoas muscle, and the left femoral anastomosis (Fig 1).
Percutaneous CT-guided drainage of the retroperitoneal process
was performed, yielding 30 mL of material. Fluid and blood
cultures were negative. Repeat CT scans demonstrated a persistent
retroperitoneal process. In June 2003, 2 weeks after admission,
operative debridement of the left groin was performed, exposing
the Dacron graft anastomosis. The abscess contained caseating
granulomatous material, which was entirely anterior and in contact
with the graft, and an intact anastomosis. Through a left flank
incision the retroperitoneum was explored. The left limb of the
ABF Dacron graft was encapsulated in a fibrous tissue plane. A
large amount of caseating material was evacuated from the entire
left graft limb and psoas muscle. The main body of the Dacron
graft was well incorporated, without evidence of involvement.
After the caseating process was debulked the exposed graft, retro-
peritoneum, psoas muscle, and groin were pulse-irrigated with 5 L
of normal saline solution, and an additional 5 L of normal saline
solution containing 300 mg of isoniazid and 600 mg of rifampin.
Intraoperative cultures were positive for acid-fast bacilli from the
retroperitoneum, and no pyogenic bacteria were cultured. Al-
though both the hospital microbiology laboratory and the Depart-
ment of Public Health state laboratory recognized acid-fast bacilli,
indicating the presence of mycobacterium, cultures at 6 weeks did
not grow M tuberculosis. The patient’s temperature returned to
normal with normalization of the white blood cell count, and
maintenance therapy included antimycobacterial medications (iso-
niazid, rifampin, ethionamide, capreomycin, ethambutol, cy-
closerine). Serial CT scans demonstrated progressive resolution of
the retroperitoneal and femoral processes. The patient has been
pain-free, afebrile, with good appetite, and gaining weight at 11
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resolving chronic inflammatory changes, without evidence of re-
current abscess (Fig 2). The patient is currently receiving an
antimycobacterial regimen of isoniazid and rifabutin, for an addi-
tional 6 to 9 months.
DISCUSSION
The abdominal aorta can become infected primarily,
usually leading to aneurysmal disease (mycotic aneurysm),
or secondarily after graft placement for treatment of aneu-
rysms or occlusive disease of the abdominal aorta. Mycotic
aneurysms are commonly infected with Salmonella species,
Staphylococcus aureus, and Clostridium septicum.1 Aortic
and aortofemoral graft infections are infrequent, with an
incidence of 1% to 2%. Responsible organism species in-
clude Staphylococcus, Streptococcus, Enterococcus, Esche-
richia, Klebsiella, Pseudomonas, Proteus, and Bacteroides.2
Primary mycobacterial infection of the abdominal and
thoracic aorta leading to aortitis or aneurysm formation is
rare, with fewer than 50 cases published in the English
literature.3,4 However, infection of aortic grafts from
Mycobacterium species has been described only once in the
literature, and the natural course and management is un-
clear. In 1977 Wright et al5 reported the first case of the
susceptibility of prosthetic aortic graft (Dacron) to
M tuberculosis placed in a patient to treat aortoiliac occlu-
sive disease. Three years after graft placement disruption of
the proximal aortic suture line and a large pseudoaneurysm
developed, which required complete graft excision and
axillobifemoral bypass. At 16-month follow-up the patient
was well and taking antituberculous medications. Since the
description of Wright et al5 there have not been any other
cases of this rare entity of mycobacterial graft infection.
The standard treatment of aortic graft infections con-
sists of resuscitation of the patient; administration of intra-
venous antibiotic agents; identification of the extent of
prosthesis infection with imaging studies, and of the arterial
Fig 1. Computed tomography scan of abdomen and pe
medium. A, Large retroperitoneal abscess is present in the
aortofemoral graft with a complex abscess with multiple
lymphadenopathy is absent. B, A separate infectious proanatomy with angiography; and extra-anatomic revascular-
ization followed by immediate or staged graft excision.6,7
In patients with significant and prohibitive medical condi-
tions and graft sepsis initial treatment can include percuta-
neous drainage, with complete or partial preservation of the
aortic graft; antibiotic irrigation; and administration of
intravenous antibiotic agents.8-10 Other methods of treat-
ing aortic graft infections include in situ reconstruction
with rifampin-bonded Dacron and polytetrafluoroethylene
prostheses,11,12 in situ reconstruction with use of lower
extremity deep veins to construct a neo-aorta,13 and in-line
reconstruction through noninfected retroperitoneum, with
infrarenal or suprarenal anastomosis followed by lower
extremity revascularization through the psoas fascia and
space of Retzius.14 However, in most instances complete
graft excision is required if there are virulent bacterial
organisms, to ensure a favorable outcome and reduced
mortality, and alternative management of infected aorto-
femoral grafts should be compared with the results of
complete graft excision and extra-anatomic revasculariza-
tion.7 The natural history and treatment of a prosthetic
aortic graft infected with tuberculosis is unknown. Surgical
dictum would favor complete graft removal, tissue debride-
ment, and extra-anatomic revascularization. In this case
report four issues were considered: revascularization if graft
removal was contemplated; an extensive mycobacterial pro-
cess in the left groin; an occluded left axillary artery and
stenosis in the right subclavian artery, which prohibited
unilateral axillofemoral bypass; and unknown guidelines in
the surgical management of tuberculosis-infected aortic
grafts. Given these unusual circumstances, a literature re-
view was performed to identify the pathophysiologic fea-
tures and treatment of a mycobacterial-infected aortic graft
and aorta. Most of the literature discusses primary infected
aorta leading to aortitis or mycotic aneurysms. The infec-
tion usually results from direct erosion from the mycobac-
terial process into the aorta (75% of cases) and hematoge-
btained in May 2003 with intravenous and oral contrast
etroperitoneal space. Process involves the left limb of the
lations (left psoas abscess not shown). Also, para-aortic
f the left groin and graft anastomosis.lvis o
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abdominal aorta are affected with equal frequency, usually
forming saccular pseudoaneurysms. Treatment includes
wide debridement of the infected aorta, with either in situ
aortic reconstruction or extra-anatomic revascularization
and antimycobacterial medications. Combining medical
and surgical treatment offers the best 30-day survival (87%-
95%).3,4,15 In 1 report 2 mycobacterial mycotic abdominal
aortic aneurysms were treated successfully with endovascu-
lar stent grafts.16
The report of Wright et al5 is the only report in the
English literature of a Dacron prosthetic graft becoming
infected with M tuberculosis, with development of a pseu-
doaneurysm after 3 years, following aortic revascularization
in a patient with known disseminated tuberculosis. Given
the paucity of information on aortic grafts infected with
mycobacterial organisms, guidelines for treatment of this
rare entity lack precedent, and management requires adop-
tion of established recommendations from the literature on
experience from common pyogenic graft infections.
With regard to our case, a number of issues warrant
further comment. Although no Mycobacterium was
grown from cultures taken at surgery, it was previously
confirmed at culture that the patient had lymphatic,
retroperitoneal, and meningeal M tuberculosis infection.
The reason for having only a positive acid-fast bacilli
stain (a definitive characteristic of mycobacteria) but no
culture of M tuberculosis organisms from the recent
operative specimen taken was likely due to the fastidious
and slow growth of M tuberculosis and the long-term
treatment with antimycobacterial medications that the
patient was receiving.
There are published reports of the treatment of giant
cell arteritis with infliximab resistant to steroids and immu-
nosuppressive drugs.17,18 Furthermore, because anti–
Fig 2. Computed tomography scan of the abdomen ob
contrast agent (severe hypothyroidism developed seco
surgical drainage. A, Retroperitoneum and graft limb dem
abscess. B, Left groin also demonstrates resolving inflamtumor necrosis factor (TNF) antibodies have the potential
to decrease host resistance to infection, there is a report of
opportunistic infection with Listeria monocytogenes in
patients given infliximab.19 It is possible that the patient in
this case study had reactivation of previously treated tuber-
culosis after infliximab, leading to disseminated tuberculo-
sis infection of the aortobifemoral graft.
Previous literature on treatment of aortic graft infec-
tions in patients at high risk has reported success with
debridement and antibiotic therapy, with graft preserva-
tion.8,9 In this case report we offered a similar approach by
performing a debulking procedure combined with intraop-
erative irrigation with an antimycobacterial solution. A
further consideration in taking this approach was that extra-
anatomic revascularization would have been limited by the
severe underlying Takayasu arteritis that affected the upper
extremities, and the infected left groin and retroperito-
neum. In addition to debridement, and as the literature
suggests in treatment of mycobacterial aortitis and mycotic
aneurysms, chronic antimycobacterial medications are im-
perative.4
Guidelines for the duration of antibiotic therapy in a
patient with a mycobacterial aortobifemoral graft infection
are unknown. We based our length of antimycobacterial
therapy on improved findings at clinical examination and
follow-up CT scans that demonstrated resolution of the
retroperitoneal and groin processes. At least 9 to 12
months of aggressive antimycobacterial drug therapy is
recommended after surgery, but indefinite maintenance
therapy may be necessary.
Although the patient in this case report did not un-
dergo graft excision but had a good outcome, the possibil-
ity of graft reinfection with proximal spread and anasto-
motic disruption is of concern in a patient with immune
system suppression, and her current condition likely reflects
d in May 2004 without iodinated intravenous and oral
to antimycobacterial medications), 11 months after
rate a resolving inflammatory process and no evidence of
n without abscess.taine
ndary
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However, surgical debulking and graft preservation, along
with intraoperative antimycobacterial antibiotic irrigation
and long-term antimycobacterial medications, and close
follow-up including imaging studies, appears effective, and
should be considered in the management of this potentially
devastating and rare condition.
REFERENCES
1. Takano H, Taniguchi K, Kuki S, Nakamura T, Miyagawa S, Masai T.
Mycotic aneurysm of the infrarenal abdominal aorta infected by
Clostridium septicum: a case report of surgical management and review
of the literature. J Vasc Surg 2003;38:847-51.
2. Bandyk DF, Esses GE. Prosthetic graft infection. Surg Clin North Am
1994;74:571-90.
3. Allins AD, Wagner WH, Cossman DV, Gold RN, Hiatt JR. Tubercu-
lous infection of the descending thoracic and abdominal aorta: case
report and literature review. Ann Vasc Surg 1999;13:439-44.
4. Long R, Guzman R, Greenberg H, Safneck J, Hershfield E. Tubercu-
lous mycotic aneurysm of the aorta: review of published medical and
surgical experience. Chest 1999;115:522-31.
5. Wright RA, Yang F, Moore WS. Tuberculous infection in a vascular
prosthesis: a case of aortic graft infection resulting from disseminated
tuberculosis. Arch Surg 1977;112:79-81.
6. Ricotta JJ, Faggioli GL, Stella A, Curl GR, Peer R, Upson J, et al. Total
excision and extra-anatomic bypass for aortic graft infection. Am J Surg
1991;162:145-9.
7. Sharp WJ, Hoballah JJ, Mohan CR, Kresowik TF, Martinasevic M,
Chalmers RT, et al. The management of the infected aortic prosthesis: a
current decade of experience. J Vasc Surg 1994;19:844-50.
8. Calligaro KD, Veith FJ, Yuan JG, Gargiulo NJ, Dougherty MJ. Intra-
abdominal aortic graft infection: complete or partial graft preservation
in patients at very high risk. J Vasc Surg 2003;38:1199-205.
9. Morris GE, Friend PJ, Vassallo DJ, Farrington M, Leapman S, Quick
CR. Antibiotic irrigation and conservative surgery for major aortic graft
infection. J Vasc Surg 1994;20:88-95.10. Glickerman DJ, Dickhoff PJ, Zierler RE, Harley JD, Dawson DL.
Successful treatment of early postoperative aortic graft infection by
percutaneous catheter drainage. Ann Vasc Surg 1996;10:486-9.
11. Hayes PD, Nasim A, London NJ, Sayers RD, Barrie WW, Bell PR, et al.
In situ replacement of infected aortic grafts with rifampicin-bonded
prostheses: the Leicester experience (1992 to 1998). J Vasc Surg
1999;30:92-8.
12. Bandyk DF, Bergamini TM, Kinney EV, Seabrook GR, Towne JB. In
situ replacement of vascular prostheses infected by bacterial biofilms. J
Vasc Surg 1991;13:575-83.
13. Clagett GP, Valentine RJ, Hagino RT. Autogenous aortoiliac/femoral
reconstruction from superficial femoral-popliteal veins: feasibility and
durability. J Vasc Surg 1997;25:255-66; discussion 267-70
14. Darling RC III, Resnikoff M, Kreienberg PB, Chang BB, Paty PS,
Leather RP, et al. Alternative approach for management of infected
aortic grafts. J Vasc Surg 1997;25:106-12.
15. Chiba Y, Muraoka R, Ihaya A, Kimura T, Morioka K, Nara M, et al.
Surgical treatment of infected thoracic and abdominal aortic aneurysms.
Cardiovasc Surg 1996;4:476-9.
16. Liu WC, Kwak BK, Kim KN, Kim SY, Woo JJ, Chung DJ, et al.
Tuberculous aneurysm of the abdominal aorta: endovascular repair
using stent grafts in two cases. Korean J Radiol 2000;1:215-8.
17. Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of
longstanding active giant cell arteritis with infliximab: report of four
cases. Arthritis Rheum 2001;44:2933-5.
18. Airo P, Antonioli CM, Vianelli M, Toniati P. Anti-tumour necrosis
factor treatment with infliximab in a case of giant cell arteritis resistant to
steroid and immunosuppressive drugs. Rheumatology (Oxf) 2002;41:
347-9.
19. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria
monocytogenes infection as a complication of treatment with tumor
necrosis factor alpha–neutralizing agents. Arthritis Rheum 2003;48:
319-24.
Submitted Jun 1, 2004; accepted Jul 28, 2004.
